Overview

  • Product name

    Anti-IL-6 antibody [EPR20653]
    See all IL-6 primary antibodies
  • Description

    Rabbit monoclonal [EPR20653] to IL-6
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, ICC/IF, IPmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Recombinant fragment within Human IL-6 aa 1 to the C-terminus. The exact sequence is proprietary.
    Database link: P05231

  • Positive control

    • WB: HUVEC treated with 0.5 µg/ml Lipopolysaccharides (LPS) for 24 hours and 300 ng/ml Brefeldin A (BFA) for 20 hours whole cell lysate. ICC/IF: HUVEC treated with Lipopolysaccharides (LPS) (0.5 µg/ml 24h) and Brefeldin A (BFA) (300 ng/ml 20h) cells. IP: HUVEC treated with 0.5 µg/ml Lipopolysaccharides (LPS) for 24 hours and 300 ng/ml Brefeldin A (BFA) for 20 hours whole cell lysate.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab214429 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 21-28 kDa (predicted molecular weight: 23 kDa).
ICC/IF 1/500.
IP 1/30.

Target

  • Function

    Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
  • Involvement in disease

    Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
    Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
  • Sequence similarities

    Belongs to the IL-6 superfamily.
  • Post-translational
    modifications

    N- and O-glycosylated.
  • Cellular localization

    Secreted.
  • Information by UniProt
  • Database links

  • Alternative names

    • Interleukin BSF 2 antibody
    • B cell differentiation factor antibody
    • B cell stimulatory factor 2 antibody
    • B-cell stimulatory factor 2 antibody
    • BSF 2 antibody
    • BSF-2 antibody
    • BSF2 antibody
    • CDF antibody
    • CTL differentiation factor antibody
    • Cytotoxic T cell differentiation factor antibody
    • Hepatocyte stimulating factor antibody
    • Hepatocyte stimulatory factor antibody
    • HGF antibody
    • HSF antibody
    • Hybridoma growth factor antibody
    • Hybridoma growth factor Interferon beta-2 antibody
    • Hybridoma plasmacytoma growth factor antibody
    • IFN-beta-2 antibody
    • IFNB2 antibody
    • IL 6 antibody
    • IL-6 antibody
    • IL6 antibody
    • IL6_HUMAN antibody
    • Interferon beta 2 antibody
    • Interferon beta-2 antibody
    • Interleukin 6 antibody
    • Interleukin 6 (interferon beta 2) antibody
    • Interleukin BSF 2 antibody
    • Interleukin-6 antibody
    see all

Images

  • All lanes : Anti-IL-6 antibody [EPR20653] (ab214429) at 1/1000 dilution

    Lane 1 : Untreated HUVEC (human umbilical vein endothelial cell line) whole cell lysate
    Lane 2 : HUVEC treated with 0.5 µg/ml Lipopolysaccharides (LPS) for 24 hours and 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Developed using the ECL technique.

    Predicted band size: 23 kDa
    Observed band size: 21-28 kDa
    why is the actual band size different from the predicted?


    Exposure time: 30 seconds


    Blocking/Dilution buffer: 5% NFDM/TBST.

    The MW observed is consistent with the literature (PMID:2523818, PMID: 2783321).

  • Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HUVEC (human umbilical vein endothelial cell line) cells, untreated or treated with Lipopolysaccharides (LPS) (0.5 µg/ml 24 hours) and Brefeldin A (BFA) (300 ng/ml 20 hours), labeling IL6 with ab214429 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing the cytoplasmic expression increased on HUVEC cells treated with Lipopolysaccharides (LPS) (0.5 µg/ml, 24 hours) and Brefeldin A (BFA) (300 ng/ml, 20 hours).

    The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) (red) at 1/200 dilution.

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.

  • IL6 was immunoprecipitated from 0.35 mg of HUVEC (human umbilical vein endothelial cell line) treated with Lipopolysaccharides (LPS) and Brefeldin A (BFA) whole cell lysate with ab214429 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab214429 at 1/1,000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10,000 dilution

    Lane 1: HUVEC treated with 0.5 μg/ml LPS for 24 hours and 300 ng/ml BFA for 20 hours whole cell lysate 10 μg (Input). 

    Lane 2: ab214429 IP in HUVEC treated with 0.5 μg/ml LPS for 24 hours and 300 ng/ml BFA for 20 hours whole cell lysate (+). 

    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab214429 in HUVEC treated with 0.5 μg/ml LPS for 24 hours and 300 ng/ml BFA for 20 hours whole cell lysate (-).

    Blocking/Dilution buffer: 5% NFDM/TBST.

    Exposure time: 3 minutes.

References

ab214429 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab214429.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up